These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants. Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040 [TBL] [Abstract][Full Text] [Related]
7. S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. Ye F; Lin X; Chen Z; Yang F; Lin S; Yang J; Chen H; Sun H; Wang L; Wen A; Zhang X; Dai Y; Cao Y; Yang J; Shen G; Yang L; Li J; Wang Z; Wang W; Wei X; Lu G Signal Transduct Target Ther; 2021 Sep; 6(1):343. PubMed ID: 34531369 [TBL] [Abstract][Full Text] [Related]
8. Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection. Feng F; Chen J; Zhao J; Li Y; Li M; Sun C Viruses; 2021 Nov; 13(11):. PubMed ID: 34835049 [TBL] [Abstract][Full Text] [Related]
9. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses. Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993 [TBL] [Abstract][Full Text] [Related]
10. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo. Havranek B; Lindsey GW; Higuchi Y; Itoh Y; Suzuki T; Okamoto T; Hoshino A; Procko E; Islam SM Commun Biol; 2023 May; 6(1):513. PubMed ID: 37173421 [TBL] [Abstract][Full Text] [Related]
11. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Chan KK; Dorosky D; Sharma P; Abbasi SA; Dye JM; Kranz DM; Herbert AS; Procko E Science; 2020 Sep; 369(6508):1261-1265. PubMed ID: 32753553 [TBL] [Abstract][Full Text] [Related]
12. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Xiao T; Lu J; Zhang J; Johnson RI; McKay LGA; Storm N; Lavine CL; Peng H; Cai Y; Rits-Volloch S; Lu S; Quinlan BD; Farzan M; Seaman MS; Griffiths A; Chen B Nat Struct Mol Biol; 2021 Feb; 28(2):202-209. PubMed ID: 33432247 [TBL] [Abstract][Full Text] [Related]
13. A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. Leach A; Ilca FT; Akbar Z; Ferrari M; Bentley EM; Mattiuzzo G; Onuoha S; Miller A; Ali H; Rabbitts TH Antiviral Res; 2021 Oct; 194():105147. PubMed ID: 34375715 [TBL] [Abstract][Full Text] [Related]
14. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA Elife; 2021 Aug; 10():. PubMed ID: 34435953 [TBL] [Abstract][Full Text] [Related]
15. ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants. Wang B; Zhao J; Liu S; Feng J; Luo Y; He X; Wang Y; Ge F; Wang J; Ye B; Huang W; Bo X; Wang Y; Xi JJ Emerg Microbes Infect; 2022 Dec; 11(1):1488-1499. PubMed ID: 35587428 [TBL] [Abstract][Full Text] [Related]
16. Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection. Guo L; Bi W; Wang X; Xu W; Yan R; Zhang Y; Zhao K; Li Y; Zhang M; Cai X; Jiang S; Xie Y; Zhou Q; Lu L; Dang B Cell Res; 2021 Jan; 31(1):98-100. PubMed ID: 33177651 [No Abstract] [Full Text] [Related]
17. Soluble ACE2 as a potential therapy for COVID-19. Krishnamurthy S; Lockey RF; Kolliputi N Am J Physiol Cell Physiol; 2021 Mar; 320(3):C279-C281. PubMed ID: 33502950 [TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835 [TBL] [Abstract][Full Text] [Related]
19. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides. Llewellyn GN; Chen HY; Rogers GL; Huang X; Sell PJ; Henley JE; Cannon PM J Virol; 2023 Aug; 97(8):e0068423. PubMed ID: 37555663 [TBL] [Abstract][Full Text] [Related]
20. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. Choudhury A; Mukherjee S J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]